Hey, Hylander, The missed timelines have put us
Post# of 36566
(Total Views: 223)
Posted On: 01/15/2020 1:43:24 PM
Hey, Hylander,
The missed timelines have put us in the position we are in. I would say that setting new timelines on many of these items and meeting them is not by itself going to reverse the situation.
What good will closing the AltuCell deal do, when we know it's another piece that will sit on the shelf without capital?
Completing the divs certainly won't boost SP.
AZ, Pantheon, Medisource, Veneto, new Olaregen product (whatever that may be)... none of those become more valuable without the capital injection.
Joe needs cash to crank up the pieces of the business pay acquisition costs, etc. He scoffed at dilution on the last call, even to the tune of 20MM shares. Assuming he wants to issue fewer shares than that implies a stock price well over $2 to raise the minimum $40MM he wants.
With the pieces of the puzzle we now have, I only see a couple of routes to raise the SP to that order of magnitude without the capital injection:
1) NGIO spins, providing "hundreds of millions" to the GNBT balance sheet
2) Excellagen takes off - $10MM marketing agreements coupled with material amounts of product sales.
3) There is buying interest from somewhere that pushes the price up on its own? I think that is highly unlikely.
As I said, I bought another 5k shares this morning @.55, so I still think it's possible. But our options are dwindling at this stock price.
GO NGIO!!!
=================
He just needs to meet some timelines and put sales together. If he can do that,
Generex can succeed.
It’s the timelines that Generex keeps moving that is causing these issues.
The missed timelines have put us in the position we are in. I would say that setting new timelines on many of these items and meeting them is not by itself going to reverse the situation.
What good will closing the AltuCell deal do, when we know it's another piece that will sit on the shelf without capital?
Completing the divs certainly won't boost SP.
AZ, Pantheon, Medisource, Veneto, new Olaregen product (whatever that may be)... none of those become more valuable without the capital injection.
Joe needs cash to crank up the pieces of the business pay acquisition costs, etc. He scoffed at dilution on the last call, even to the tune of 20MM shares. Assuming he wants to issue fewer shares than that implies a stock price well over $2 to raise the minimum $40MM he wants.
With the pieces of the puzzle we now have, I only see a couple of routes to raise the SP to that order of magnitude without the capital injection:
1) NGIO spins, providing "hundreds of millions" to the GNBT balance sheet
2) Excellagen takes off - $10MM marketing agreements coupled with material amounts of product sales.
3) There is buying interest from somewhere that pushes the price up on its own? I think that is highly unlikely.
As I said, I bought another 5k shares this morning @.55, so I still think it's possible. But our options are dwindling at this stock price.
GO NGIO!!!
=================
He just needs to meet some timelines and put sales together. If he can do that,
Generex can succeed.
It’s the timelines that Generex keeps moving that is causing these issues.
(3)
(0)